Leerink Partners Remains a Buy on United Therapeutics Corporation (UTHR) With a $408 PT

United Therapeutics Corporation (NASDAQ:UTHR) is one of the most profitable biotech stocks to invest in now. In a report released on July 23, Roanna Ruiz from Leerink Partners maintained a Buy rating on United Therapeutics Corporation (NASDAQ:UTHR) with a price target of $408.00, basing the rating on the company’s growth and stability.

Ruiz expects United Therapeutics Corporation (NASDAQ:UTHR) to undergo meaningful growth in its Tyvaso franchise, especially in the PH-ILD market, which may support the base business.

He also considers the upcoming Phase 3 TETON-2 IPF data, which is anticipated in the second half of 2025, to be a critical catalyst that may considerably boost United Therapeutics Corporation (NASDAQ:UTHR) stock in the case of positive results.

In addition, United Therapeutics Corporation (NASDAQ:UTHR) has strong relationships with key physicians, strategic positioning with payers, and an established commercial presence, factors that Ruiz considers helpful in mitigating competitive pressures.

United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company that develops and commercializes products for patients with chronic and life-threatening conditions. Its product portfolio includes Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin.

While we acknowledge the potential of UTHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.